Natera Sets $6 Billion Revenue Goal For 2029 As Moshkevich Replaces Chapman As CEO
The new CEO says doubling revenue in three years needs "no big miracles," with early cancer screening barely counted in the plan.
Natera, the diagnostics company behind the Signatera cancer test, is aiming for $6 billion in revenue in 2029, new CEO Solomon Moshkevich said on the company's earnings call Thursday, taking over from Steve Chapman. He said the target, double current revenue in three years, needs almost nothing from its early cancer screening business.
A target built on Signatera pricing
Moshkevich said it is not Natera's habit to publish long-term financial targets. The last one, set in 2022, was cash flow break-even in 2024, and the company hit it. "We didn't achieve that by making miracles happen," he said, and he called $6 billion "highly achievable" even with minimal contribution from screening.
Answering a TD Cowen analyst, he said the goal can be met without Signatera's average selling price getting much beyond $1,450. CFO Michael Brophy put current prices at around $1,290 and called $1,450 "eminently achievable." Brophy also called the goal "aggressive," one set to galvanize the company, and said he would be disappointed if Natera could not enter a few larger clinical practice guideline areas.
Moshkevich told a Leerink Partners analyst that early cancer screening will be "a relatively small contributor in 28 and 29," with a readout from the FIND trial planned for late next year. He said pharma and data licensing would add several hundred million dollars in 2029.
A handoff from "a position of strength"
Chapman, who joined Natera in 2010 and spent almost eight years as CEO, said revenue rose roughly tenfold under his tenure. He will stay on as a consultant and as an adviser to the board. Moshkevich, hired in 2011, is Natera's third CEO.
Asked about the timing, Moshkevich said Chapman and the board agreed "the time is right for a leadership transition from a position of strength." On strategy, he said: "you're not going to see any big radical change."
Natera's third-quarter revenue was $794 million, up about 34% from $592 million a year earlier, and management raised its full-year revenue guidance by $140 million at the midpoint. Brophy said the company spends more than $100 million on early cancer detection that generates zero revenue, which he said hides the scale it has already reached. The company's market value was $56.4 billion in the latest session data.
Japan and the FIND readout
Management said it expects a pricing and reimbursement update on its Japan colorectal and bladder cancer launch at the JPMorgan conference, if not sooner. The FIND trial readout is planned for late next year.
Brophy also guided to operating expense growth of 10% to 12% in 2027, with early cancer detection and clinical trials the biggest drivers.
Sources
- Natera Shares Slide on Wider-Than-Expected Loss, CEO Transition — MarketWatch
- Natera (NTRA) Reports Q3 Loss, Beats Revenue Estimates — Yahoo Finance
- Natera: Q3 Earnings Snapshot – WTOP News — wtop.com
- Natera: Q3 Earnings Snapshot — Associated Press
- Natera GAAP EPS of -$0.42 misses by $0.15, revenue of $794M beats by $86.5M (NTRA:NASDAQ) — seekingalpha.com